Gill, H HDesai, H GMehta, P RRanganathan, SKalro, R HMurti, P KPrabhu, S R1991-10-012009-05-311991-10-012009-05-311991-10-01Gill HH, Desai HG, Mehta PR, Ranganathan S, Kalro RH, Murti PK, Prabhu SR. Mono and dual therapy for Helicobacter pylori associated gastritis. Journal of the Association of Physicians of India. 1991 Oct; 39(10): 743-5http://imsear.searo.who.int/handle/123456789/91511Sixty patients with Helicobacter Pylori positive non ulcer dyspepsia were randomly allocated to one of the following treatment groups: Group I--norfloxacin 400 mg bid for 10 days, Group II--amoxycillin 500 mg bid plus tinidazole 500 mg bid for 15 days, Group III--colloidal bismuth subcitrate (CBS) 240 mg bid for 4 weeks. H pylori elimination was achieved in 14%, 81%, and 62% in Groups I, II and III respectively. Eradication of H pylori was not observed in Groups I and II, but was achieved in 25% of patients in Group III. Antral gastritis improved in 69% in Group II and 50% in Group III. We conclude that norfloxacin is not effective in H pylori infection. A combination of amoxycillin and tinidazole is highly effective in H pylori elimination with improvement in associated gastritis, but H pylori eradication is not observed with this therapy. CBS is also effective in H pylori elimination though H pylori eradication is achieved in only 25%.engAdultAmoxicillin --therapeutic useAntacids --therapeutic useAnti-Bacterial Agents --therapeutic useAnti-Ulcer Agents --therapeutic useDrug Therapy, CombinationGastritis --drug therapyHelicobacter Infections --drug therapyHelicobacter pylori --drug effectsHumansNorfloxacin --therapeutic useOrganometallic Compounds --therapeutic useTinidazole --therapeutic useClinical Trial